+966 568813716 [email protected]

E-Lessons

Home / Archive by category "E-Lessons" (Page 10)
14
Jul
2018
CLOZAPINE
Posted On July 14, 2018  By Dr.Adel Serag  And has No Comment

Clozapine What’s of Interest: Clozapine REMS and ANC monitoring update Brands Clozaril, Leponex, Versacloz (oral suspension), Fazaclo ODT (oral disintegrating tablet) Class Atypical antipsychotic (serotonin-dopamine antagonist; second-generation antipsychotic; also a mood stabilizer) Approved For: Treatment-resistant schizophrenia   Reduction in risk of recurrent suicidal behavior in patients […]

Read More

12
Jul
2018
Agomelatin = Valdoxan
Posted On July 12, 2018  By Dr.Adel Serag  And has No Comment

1 AGOMELATINE THERAPEUTICS Brands • Valdoxan see index for additional brand names Generic? No Class • Neuroscience-based Nomenclature: melatonin multi-modal (Mel-MM) • Agonist at melatonergic 1 and melatonergic 2 receptors • Antagonist at 5HT2C receptors Commonly Prescribed for (bold for FDA approved) • Depression How the […]

Read More

11
Jul
2018
Lurasidone : Latuda
Posted On July 11, 2018  By Dr.Adel Serag  And has No Comment

What’s of Interest: Latuda is now approved for pediatric bipolar depression (ages 10 and older) Brands Latuda Class Atypical antipsychotic (serotonin-dopamine antagonist; second generation antipsychotic; also a mood stabilizer) Approved For: Schizophrenia (ages 13 and older) Bipolar depression (ages 10 and older, monotherapy) Bipolar depression (adults, […]

Read More

04
Jul
2018
Psychiatry’s ‘C’ words
Posted On July 4, 2018  By Dr.Adel Serag  And has No Comment

      Current Psychiatry. 2018 July;17(7):4,6 By Henry A. Nasrallah, MD Recently, contemporary “culture” has capriciously confounded and confused our national community with a cringe-worthy “C” word. Unfortunately, this was followed by only transient public consternation, reflecting the coarsening of our social communication and discourse and the cant of many. But the ripple effects continue. As […]

Read More

04
Jul
2018
New marijuana-based pharmaceutical drug approved by FDA
Posted On July 4, 2018  By Dr.Adel Serag  And has No Comment

What is Epidiolex? Epidiolex is an oral liquid-based drug made from the cannabidiol (CBD) portion of cannabis. Compared to the tetrahydrocannabinol (THC) portion, CBD is not psychoactive, so taking this drug would not result in a high for the user. CBD acts on different parts of […]

Read More

02
Jun
2018
May 21, 2018   :FDA Approves First Non-Opioid to Treat Opioid Withdrawal Symptoms 
Posted On June 2, 2018  By Dr.Adel Serag  And has No Comment

    The US FDA has approved the first non-opioid treatment for the relief of opioid withdrawal symptoms. The medication, lofexidine hydrochloride (trade name Lucemyra), is an oral, selective alpha-2 adrenergic receptor agonist that reduces the release of norepinephrine, which may lead to relief of autonomic […]

Read More

13
Apr
2018
Beyond DSM-5: Clinical and biologic features shared by major psychiatric syndromes
Posted On April 13, 2018  By Dr.Adel Serag  And has No Comment

Current Psychiatry. 2017 October;16(10):4,6-7 Author(s): Henry A. Nasrallah, MD Author and Disclosure Information Imagine the rich landscape of psychopathology as an Amazon jungle. The DSM diagnostic schema describes the individual trees but overlooks the fascinating patterns within the forest. It does not adequately inform psychiatric practitioners about […]

Read More

13
Apr
2018
Advancing clinical neuroscience literacy among psychiatric practitioners
Posted On April 13, 2018  By Dr.Adel Serag  And has No Comment

Current Psychiatry. 2017 September;16(9):17-18 Author(s): Henry A. Nasrallah, MD Author and Disclosure Information It is time for psychiatric clinicians to move beyond the traditional practice of describing psychopathology in terms of signs and symptoms, which is perpetuated by the DSM diagnostic schemas. An abundance of recent neuroscience […]

Read More

13
Apr
2018
The crisis of poor physical health and early mortality of psychiatric patients
Posted On April 13, 2018  By Dr.Adel Serag  And has No Comment

Current Psychiatry. 2018 April;17(4):7-8,11 Author(s): Henry A. Nasrallah, MD Author and Disclosure Information PDF PDF PDF DOWNLOAD It is well established that general medical conditions can be associated with various psychiatric disorders. But the reverse is less recognized: That serious mental illness is associated with many physical maladies, often […]

Read More

08
Apr
2018
Is there a place for cannabidiol (CBD) in the treatment of psychiatric disorders?
Posted On April 8, 2018  By Dr.Adel Serag  And has No Comment

    Cannabidiol (CBD) is considered to be a nonpsychotomimetic and nonpsychoactive derivative of Cannabis sativa. It was patented by the US Department of Health and Human Services in 2003 as an antioxidant and neuroprotectant. CBD has a complex mode of action which includes inverse agonism (functionally an […]

Read More


Page 10 of 34